Chemotherapy — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Chemotherapy is the use of cytotoxic (cell-killing) drugs to destroy rapidly dividing cancer cells by interfering with DNA replication, cell division, or specific molecular targets within tumour cells. Drugs are administered intravenously (most common), orally, intrathecally (into cerebrospinal fluid), or intraperitoneally depending on the cancer type. Most chemotherapy regimens are given in cycles every 2–4 weeks over a total treatment duration of 3–6 months. A cycle consists of treatment days followed by a recovery period during which normal blood counts are allowed to recover before the next dose. Chemotherapy may be delivered in several clinical settings: neoadjuvant (before surgery to shrink a tumour and allow less extensive surgery), adjuvant (after surgery to eliminate micrometastatic disease and reduce recurrence risk), concurrent (with radiotherapy to potentiate its effects), or palliative (to control advanced cancer, extend survival, and maintain quality of life). Common drug classes include alkylating agents (cyclophosphamide, cisplatin), antimetabolites (5-fluorouracil, methotrexate), anthracyclines (doxorubicin, epirubicin), taxanes (paclitaxel, docetaxel), topoisomerase inhibitors (irinotecan, etoposide), and vinca alkaloids (vincristine, vinblastine). Modern oncology increasingly combines conventional chemotherapy with targeted agents and immunotherapy. Chemotherapy is the use of cytotoxic drugs to destroy rapidly dividing cancer cells by interfering with DNA replication, cell division, or specific molecular targets within tumour cells. Drugs are administered intravenously (most common), orally, intrathecally (into cerebrospinal fluid), intraperitoneally, or via regional infusion depending on the cancer type and location. Chemotherapy may be used with curative intent as primary treatment, as neoadjuvant therapy (before surgery) to reduce tumour size and improve resectability, as adjuvant therapy (after surgery) to eliminate microscopic residual disease, or as palliative therapy to control advanced disease and improve quality of life. Modern oncology increasingly combines cytotoxic chemotherapy with targeted therapies, immunotherapy checkpoint inhibitors, and hormonal agents. Chemotherapy is administered by medical oncologists and haematologists in specialist cancer centres or outpatient infusion suites. Precision oncology — matching chemotherapy regimens to tumour genomic profiles — has become standard of care, particularly in colorectal, lung, and breast cancers.

Chemotherapy is used across a wide spectrum of haematological and solid tumour malignancies. The decision to recommend chemotherapy depends on cancer type and stage, tumour molecular biology, patient performance status (ECOG scale 0–4), comorbidities, and evidence from randomised clinical trials. Major indications include: adjuvant chemotherapy for high-risk early breast cancer (anthracycline-taxane regimens such as AC-T or FEC-D), adjuvant colorectal cancer (FOLFOX, CAPOX), and non-small cell lung cancer post-resection; curative chemotherapy for Hodgkin's lymphoma (ABVD), testicular cancer (BEP), and diffuse large B-cell lymphoma (R-CHOP); neoadjuvant chemotherapy for locally advanced breast cancer, oesophageal cancer (FLOT), and bladder cancer (MVAC/GC); and palliative chemotherapy for metastatic disease (lung, colorectal, gastric, pancreatic, and many others). Platinum-based regimens (carboplatin, cisplatin) are the backbone of lung, ovarian, bladder, head and neck, and testicular cancer treatment. Anthracyclines (doxorubicin, epirubicin) are central to breast and soft tissue sarcoma regimens. Genomic testing (Oncotype DX, MammaPrint) now guides chemotherapy decisions in early breast cancer, avoiding treatment in patients unlikely to benefit.

Before each chemotherapy cycle, a full blood count (FBC) and renal/hepatic function tests are checked to confirm the patient can safely receive treatment. Patients are pre-medicated with anti-emetics (ondansetron, dexamethasone, aprepitant) to prevent nausea and vomiting. Intravenous chemotherapy is delivered via a peripheral IV cannula or, for repeated administration, through an implanted venous access device — a PICC line (peripherally inserted central catheter), a Hickman or Groshong central line, or a port-a-cath (subcutaneous implanted port). Drug infusion times vary enormously: anthracyclines may be given as a bolus over 15–20 minutes, while paclitaxel infusions take 3 hours (weekly) or 3 hours (3-weekly), and fluorouracil infusions may run over 46 hours via ambulatory pump. Dose is calculated based on body surface area (BSA, calculated from height and weight) or, for newer agents, by fixed dosing or body weight. GCSF (granulocyte colony-stimulating factor, e.g., filgrastim, pegfilgrastim) is administered after cycles with high neutropenia risk to stimulate bone marrow recovery and reduce the risk of febrile neutropenia. Oral chemotherapy agents (capecitabine, temozolomide, cyclophosphamide tablets) are taken at home according to a prescribed schedule. Before each chemotherapy cycle, a full blood count and renal and hepatic function tests confirm the patient can safely receive treatment. Anti-emetics (ondansetron, dexamethasone, aprepitant) are administered before infusion to prevent nausea and vomiting. Intravenous chemotherapy is administered through a peripheral cannula, peripherally inserted central catheter (PICC), or a surgically implanted port-a-cath for repeated cycles or vesicant agents. Each infusion session takes 30 minutes to 8 hours depending on the agent and cycle. Treatment cycles are repeated every 2–4 weeks, with the interval allowing marrow recovery. Total course length is typically 3–6 months for curative-intent regimens. Oral chemotherapy agents (capecitabine, cyclophosphamide, temozolomide) are taken at home — strict dose timing, storage, and safe handling instructions are provided. Dose modifications based on toxicity and renal/hepatic function are made by the oncologist at each cycle assessment.

The effectiveness of chemotherapy varies dramatically by cancer type, stage, and regimen, ranging from potentially curative to life-extending. Curative intent chemotherapy achieves remission in 80–90% of testicular cancer patients, 70–80% of Hodgkin's lymphoma patients, and 60–70% of diffuse large B-cell lymphoma patients. Adjuvant chemotherapy reduces breast cancer recurrence risk by 30–50% relative risk reduction and has contributed significantly to falling breast cancer mortality over the past three decades. Neoadjuvant chemotherapy for oesophageal cancer (FLOT regimen) improves 3-year survival from 48% to 57% compared to surgery alone (FLOT4 trial). In metastatic settings, palliative chemotherapy extends median survival, maintains quality of life, and reduces cancer-related symptoms. Modern combination regimens — chemotherapy plus immunotherapy (pembrolizumab, nivolumab) — have further improved response rates and survival in lung, colorectal, gastric, and triple-negative breast cancer, with overall response rates exceeding 60% in selected populations. The oncology team will set treatment goals (curative, adjuvant, or palliative) and realistic expectations based on cancer type and individual circumstances.

Chemotherapy affects rapidly dividing cells throughout the body, not only cancer cells, producing predictable toxicities in the bone marrow, gastrointestinal tract, hair follicles, and reproductive organs. Common side effects include: nausea and vomiting (managed with modern anti-emetic protocols — 5-HT3 antagonists, NK1 antagonists, dexamethasone — in over 80% of high-emetogenic regimens); fatigue (near universal, peaks days 5–10 after each cycle); alopecia (hair loss) from taxanes and anthracyclines (reversible; scalp cooling reduces risk by 30–50%); mucositis (oral sores) from methotrexate, 5-FU, and anthracyclines; myelosuppression (neutropenia, anaemia, thrombocytopenia) reaching nadir at days 10–14. Febrile neutropenia — fever above 38°C with absolute neutrophil count below 0.5×10⁹/L — is a medical emergency requiring immediate hospitalisation and IV broad-spectrum antibiotics (piperacillin-tazobactam or ceftazidime). Specific long-term toxicities include peripheral neuropathy (taxanes, oxaliplatin — often irreversible at high cumulative doses), cardiotoxicity (anthracyclines — LVEF monitoring required), nephrotoxicity (cisplatin — aggressive IV hydration required), ototoxicity (cisplatin), and secondary myeloid leukaemia (alkylating agents — rare, <2% lifetime risk).

The inter-cycle recovery period (typically 14–21 days) allows bone marrow recovery and resolution of acute side effects. Common effects — fatigue, nausea, and mucositis — typically peak at days 3–7 post-infusion, improve significantly by day 10, and largely resolve before the next cycle. A full blood count (FBC) is performed on day 14–17 to check the neutrophil nadir. Persistent neutropenia may require dose reduction or cycle delay. Dietary advice during chemotherapy focuses on maintaining caloric intake, managing nausea with small frequent meals, and ensuring adequate hydration (2 litres daily minimum). Anti-nausea medications are prescribed as a take-home pack for use in the days after infusion. Patients should avoid crowds and individuals with infections during the neutropenic phase (days 7–14). Strenuous exercise is generally avoided on infusion days and in the first 48 hours; light walking and gentle activity are encouraged throughout the treatment course. Psychological support, including clinical nurse specialist input, peer support groups, and clinical psychology referral, addresses the significant emotional burden of chemotherapy treatment.